2024
Real-World Efficacy and Patient-Reported Quality of Life Outcomes with Daratumumab Regimens in Multiple Myeloma
Browning S, Li F, Theprungsirikul P, Parker T, Bar N, Giri S, Anderson T, Stevens E, Gorshein E, Sabbath K, Wei C, Ali S, Witt D, Persico J, Talsania A, Rahmat L, Kidwai W, Legare R, LaSala J, Austin M, Neparidze N. Real-World Efficacy and Patient-Reported Quality of Life Outcomes with Daratumumab Regimens in Multiple Myeloma. Blood 2024, 144: 7831. DOI: 10.1182/blood-2024-204150.Peer-Reviewed Original ResearchRelapsed/refractory multiple myelomaInternational Myeloma Working GroupAdverse eventsGlobal health statusFunctional scalesMultiple symptom scalesPartial responseProteasome inhibitorsMultiple myelomaHealth statusEastern Cooperative Oncology Group performance statusClinical trialsMonoclonal antibody targeting CD38Median progression free survivalRelapsed/refractory multiple myeloma patientsIntroduction of novel therapiesHealth-related quality of lifeClinical response assessmentDaratumumab-based regimensProgression free survivalInfusion-related reactionsLines of therapyPatient-reported quality of life outcomesMean fatigue scoreHealth-related quality
2018
Atezolizumab in Combination with Daratumumab with or without Lenalidomide or Pomalidomide: A Phase Ib Study in Patients with Multiple Myeloma
Cho H, Costa L, Davies F, Neparidze N, Vij R, Feng Y, Teterina A, Fritsch E, Wenger M, Kaufman J. Atezolizumab in Combination with Daratumumab with or without Lenalidomide or Pomalidomide: A Phase Ib Study in Patients with Multiple Myeloma. Blood 2018, 132: 597. DOI: 10.1182/blood-2018-99-114960.Peer-Reviewed Original ResearchObjective response rateAdverse eventsMultiple myelomaMM ptsGenentech IncGrade 3Response assessmentNon-small cell lung cancerHigh-risk cytogenetic featuresAdvisory CommitteeF. Hoffmann-La Roche LtdR Multiple MyelomaGood partial responseGrade 4 thrombocytopeniaImmune checkpoint inhibitorsPhase Ib studyNew safety signalsProgression-free survivalRefractory multiple myelomaSerious adverse eventsCell lung cancerDuration of responseAnti-myeloma activityBenefit-risk profileData monitoring committee